The drug has a low potential for interactions via cytochrome P450 (CYP) liver enzymes and transporter proteins. The only relevant finding in studies was a reduction of<unk>  blood levels when combined with the strong CYP3A4 inducer rifampicin. The Cmax was reduced by 54% and the area under the curve by 74% in this study.
Ixazomib
Carfilzomib
Bortezomib
Vincristine
Carmustine
Ifosfamide
Busulfan
Lenalidomide